Editas Medicine, Inc. (EDIT)

NMS – Real Time Price. Currency in USD

2.85

+0.11 (4.01%)

At close: Jun 26, 2026, 4:00 PM EDT

2.84

-0.01 (-0.35%)

After-hours: Jun 26, 2026, 7:25 PM EDT

04.06.2026

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

28.05.2026

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.

26.05.2026

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $2.25. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million (assuming no exercise of the common stock warrants), before deducting underwriting discounts and commissions and offering expenses. If all of the common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.

26.05.2026

Editas Medicine Announces Proposed Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof). All of the securities in the offering are to be sold by Editas Medicine.

26.05.2026

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple atherogenic lipoproteins Company on track to submit CTN by mid-2026 for EDIT-401 and achieve early in vivo human proof-of-concept data by the end of 2026 CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece on May 25, 2026.

14.05.2026

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months

06.05.2026

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.

Videos

No Data

There is no data to display

Press releases

26.05.2026

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

26.05.2026

Editas Medicine Announces Proposed Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof). All of the securities in the offering are to be sold by Editas Medicine.

26.05.2026

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

14.05.2026

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine, Inc. (EDIT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Editas Medicine, Inc. (EDIT)

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Videos

No Data

Press releases

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Videos

No Data

Press releases

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Search stocks

Editas Medicine, Inc. (EDIT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Editas Medicine, Inc. (EDIT)

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Videos

No Data

Press releases

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Videos

No Data

Press releases

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting